Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC)

Wojciech Naumnik, Maria Ossolinska, Katarzyna Niewiarowska, Elzbieta Chyczewska. Department of Pulmonology, Medical University of Bialystok, Bialystok, Poland

There are several factors involved in angiogenesis, not tested yet, whose role is not clear in patients with lung cancer. Our pilot study was carried out to analyze the serum IL-20, Galectin 3, IL-29 and IL-33 (ELISA) in patients with non-small cell lung cancer (45 NSCLC) before chemotherapy, 15 sarcoidosis (BBS), 8 hypersensitivity pneumonitis (HP) and 15 healthy controls (H). Serum concentration of IL-20 was highest in NSCLC, lower in BBS and H, and lowest in HP (45.1±2 vs 41.88±11 vs 40±5.5 vs 36.09±2.7 pg/ml; p=0.01). The levels of Galectin 3 was highest in HP, lower in BBS, NSCLC, lowest in H (2.5±0.3 vs 1.2±0.4 vs 0.9±0.5 vs 0.8±0.1 pg/ml; p=0.03). The highest level of IL-29 was in HP, lower in NSCLC and H, the lowest in BBS (85.70±12 vs 53.65±2.8 vs 45.22±2.5 vs 38.68±1.7 pg/ml; p=0.003). Serum levels of IL-33 was lowest in H, higher in NSCLC and BBS, the highest in HP (5.56±5.7 vs 7.24±1.5 pg/ml; p=0.02). Serum levels of IL-29 and IL-33 were lower in patients with metastases of NSCLC (IL-29: 85.19±18 vs 48.33 pg/ml; p=0.03, IL-33: 4.54±4.2 vs 3.61±2.1 pg/ml; p=0.04). There were no significant differences in serum IL-20, Galectin 3, IL-29 and IL-33 in relation to a response to a therapy. A correlations were found between IL-33 and Galectin 3 concentrations (R= 0.60). Summing up, serum concentrations of IL-20, Galectin 3, IL-29 and IL-33 were higher in patients with NSCLC than in healthy people. Their clinical usefulness in the diagnosis of cancer seems to be weak, but this requires further investigation.

Diagnostic accuracy of SELDI-TOF-MS (surface enhanced laser desorption/ionization time of flight mass spectrometry) method in early diagnosis of lung cancer

Cetburl Simsek1, Özlem Sönmez1, Ahmet Yurdakul2, Füsun Özmaz2, Nurullah Zengin1, Atilla Keyfi1, Dilek Kubilay1, Özlem Gurbahar3, Senem Karatayli3, Mithat Bozdayi4, Can Öztürk5, 1Atatürk Chest Disease and Surgery Research Hospital, Department of Pulmonary Medicine, Ankara, Turkey; 2Gazi University, Faculty of Medicine, Department of Pulmonary Medicine, Ankara, Turkey; 3Numune Hospital, Department of Oncology, Ankara, Turkey; 4Oncology Hospital, Department of Oncology, Ankara, Turkey; 5Gazi University, Faculty of Medicine, Department of Biochemistry, Ankara, Turkey; 6Ankara University, Faculty of Medicine, Institute of Hepatology, Ankara, Turkey

Objective: Early diagnosis of lung cancer is critical for successful treatment and improving the outcome of patients. The cancer cells synthesize proteins as well as all of the other cells. Cancer may be recognised with these proteins profiles analysed with any methods. With SELDI-TOF-MS method, protein profiles can be obtained from serum, pleural fluid, urine and tissue samples. The goal of this study was to identified protein profiles and to distinguish lung cancer patients from healthy individuals by serum protein profiles.

Methods: 170 patients with lung cancer, 53 individuals with no evidence lung cancer but high risk for lung cancer and 47 healthy individuals totally 270 individuals were included in this study. Venous samples were taken from all cases. All of the serum samples were analyzed by SELDI/TOF-MS method for proteomics investigation.

Abstract printing supported by Chiesi. Visit Chiesi at Stand D.30
Results: SELDI-TOF spectra of patients with lung cancer, healthy control and high risk are shown for the most discriminatory peaks of 11480 m/z, 11547 m/z and 11679 m/z. Discriminatory proteomic features between lung cancers and healthy controls:

<table>
<thead>
<tr>
<th>Proteomic feature (m/z)</th>
<th>p value</th>
<th>AUROC</th>
<th>Average intensity of lung cancer cases</th>
<th>Average intensity of healthy controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>11480</td>
<td>3.12</td>
<td>0.88</td>
<td>1.24</td>
<td>0.88</td>
</tr>
<tr>
<td>11547</td>
<td>1.35</td>
<td>0.87</td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>11679</td>
<td>4.87</td>
<td>1.03</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

These proteomic features were present in only lung cancer group, but not in healthy control or high risk groups.

Conclusion: SELDI-TOF-MS method can correctly distinguish patients with lung cancer from healthy individuals and SELDI-TOF-MS method may be a new tool in diagnosis and screening test for lung cancer.

4502 Bioco nductance as adjunctive technique for evaluation of patients with lung masses detected by chest CT

Kareen Callahan, Rex Yung, Ming-Ying Zeng, Michael Garff. Clinical Affairs, Fres cMedx Inc, Salt Lake City, UT; United States Medicine and Oncology, Div of Pulmonary Critical Care, Johns Hopkins University, Baltimore, MD, United States Medicine, Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, MD, United States

Introduction: CT screening may reduce LC mortality in high risk subjects but also finds many masses with indeterminate features resulting in invasive procedures for benign lesions.

Aims: We hypothesize that trans-thoracic bioclectrical conductance measurements may discriminate benign from malignant CT-detected lesions.

Methods: 41 subjects with CT-detected masses and or lung cancer symptoms such as cough, hoarseness, dyspnea, hemoptysis, weight loss or recurrent respiratory infections enrolled. Prior to biopsy, measured 9 parameters at 62 sites were conducted with Biocconduction Scan Platform (BSP). For each subject a composite score from collected data was calculated and an optimal cut-point set to discriminate between the malignant and benign outcomes selected.

Results: 26 pathology-confirmed NSCLC, 2 SCLC, 1 carcinoma whereas 12 had a benign outcome based on pathology (9) or stable follow-up CT (3). BSP data for LC cases: 26 true positives, 3 false negatives (including the carcinoma), 90% sensitivity. For benign cases, the BSP resulted in 1 false positive,11 true negatives, 92% specificity. The overall ROC from BSP analysis was 91%.

Conclusion: BSP bioco nductance measurements is associated strongly with a thoracic cancer or benignity. A technology that non-invasively provides adjunctive information to CT scanning to decide whether biopsy or further follow-up is appropriate will be an important clinical tool.

4503 Amorphous components of the extracellular matrix have impact as new biochemical markers on malignancy characterization and prognosis of non-small cell lung cancer

Maria Stella Peres Rangel1, Vanessa Karen de Sá1, João Roberto Maciel Martins2, Edwin Roger Parra1, Aline Mendes1, Dirce Carrazzo3, Elóiça Olivié2, Vera Luiza Capezotto1,4,5.1Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil; 2Biochemistry and Molecular Biology, Universidade Federal de São Paulo, São Paulo, SP, Brazil; 3Pathology, Hospital AC Camargo, São Paulo, SP, Brazil

Introduction: Many have reported that glycosaminoglycans (GAGs) have different behaviors in the presence of malignant tissues. In this study, we examined different GAGs concentrations and their impact on diagnosis and/or prognosis of patients with non small cell lung cancer.

Methods: Sulfated GAGs and Hyaluronic Acid (HA) were examined in tumoral and non-tumoral tissues from 45 lung cancer patients. Tissue samples were dehydrated and incubated with a proteolytic enzyme. The levels of HA were measured by a noncompetitive ELISA-like fluorometric assay. The sulfated GAG chains (heparan, dermatan and chondroitin sulfate - HS, DS and CS), were precipitated, dissolved in DNAse and their concentrations were identified after gel electrophoresis.

Results: HS and HA showed significantly higher concentrations in tumoral than in normal areas (p=0.02 and p=0.0001, respectively; Fig. 1A/B). The Kaplan-Meier survival curves shows that tissues with lower concentrations of HA have better long-term survival than those with higher concentrations (Log Rank=3.59; p=0.05; Fig. 1C). One hundred% of tumoral areas presented CS while the normal almost never (p=0.0001; Fig. 1D).

Conclusion: The results presented suggest a possible role of these molecules on lung cancer development, but more importantly provide potential biochemical markers for differentiating normal from lung cancer patients.

4504 Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer

Nobuhisa Ishikawa1, Noboru Hattori1, Sonosuke Tanaka1, Yasushi Horimasa1, Akihito Yokoyama1, Nobuo Kohn1, 1Departments of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; 2Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Japan

Background: The type I interferon receptor subunit, interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2), has been reported to be overexpressed in sev eral malignancies, primarily adenocarcinomas (ADCs). However, the biological significance of IFNAR2 in human lung cancer has not yet been studied.

Methods: Immunohistochemical analysis of 113 surgically resected non-small cell lung cancer specimens was performed. Serum concentrations of IFNAR2 were also determined by an enzyme-linked immunosorbent assay in 157 lung cancer patients and 164 healthy volunteers.

Results: IFNAR2 overexpression was observed in all histological types of lung cancers examined. Furthermore, strong IFNAR2 expression was associated with shorter progression-free survival (PFS) and overall survival (OS) (p < 0.0001 and p = 0.0110, respectively) in non-small cell lung cancer patients. Multivariate analyses confirmed its independent prognostic value for PFS and OS (p < 0.0001 and p = 0.0222, respectively). IFNAR2 serum levels were also significantly higher in lung cancer patients than in healthy volunteers (p = 0.001).

Conclusions: IFNAR2 overexpression was observed in various histological types of lung cancers, and appears to be associated with lung cancers that behave aggressively. The results of this study strongly support the potential of IFNAR2 as a diagnostic and prognostic biomarker for lung cancer.

4505 SHOX2 DNA methylation is a promising biomarker for the diagnosis of lung cancer in plasma

Bernd Schmidt1, Christoph Kneip2, Anke Seegebarth1, Michael Fleischhacker4, Volker Liebenberg1, 1Pneumology, University Hospital Halle, Halle, Germany; 2Pneumology, University Hospital Charité, Berlin, Germany; 3Molecular Diagnostics, Theraclouds GmbH, Mainz, Germany; 4Molecular Diagnostics, Bavarian Nordic GmbH, Berlin, Germany; 5Molecular Diagnostics, Epigenomics AG, Berlin, Germany

Background & objectives: SHOX2 DNA methylation (5mSHOX2) has been shown...
previously to identify lung cancer in bronchial aspirates and a test for **SHOX2** is available in Europe as an IVD test to aid pathologists in the diagnosis of lung cancer. DNA methylation biomarkers can also be used to detect tumor-derived circulating DNA in blood. The objective of the present study was to develop a modified assay for detection of **SHOX2** in plasma to determine the clinical performance in patients.

**Methods:** A real time PCR duplex assay originally developed for quantification of **SHOX2** in a high background of unmethylated DNA in bronchial aspirates was modified for the unique requirements of plasma. Following assay optimization, quantitative real-time PCR was used to analyze **SHOX2** in plasma samples (**n = 411**). A training study was performed to determine a cut-off for patient classification (**n = 20** lung cancer patients; **n = 20** controls) and the resulting cut-off was verified in a testing study (**n = 202** stage I – IV lung cancer patients, **n = 169** controls, including patients with other cancers like e.g. of prostate).

**Results:** The assay reliably detected 15 pg of methylated DNA in a background of 50,000 pg unmethylated DNA. The **SHOX2** assay differentiated lung cancer patients from controls with a sensitivity of 60% and a specificity of 90%. Patients with stages II (72%), III (55%) and IV (83%) lung cancer were detected at a higher sensitivity as compared with stage I patients (27%). Small-cell lung cancer (80%) and squamous cell carcinoma (63%) were detected at higher sensitivity than adenocarcinoma (39%).

**Conclusions:** **SHOX2** is a promising biomarker for detection of malignant lung disease in plasma.

### 4506

**Circulating tumor cells in chronic obstructive pulmonary disease patients**

Céline Sanflorenzo1,2, Karine Risso1, Valérie Sellam2, Véronique Hofman1,4,5, Marius Ilie1,4, Elodie Long6, Eric Selva7, Christine Bonnetaud5, Charles-Hugo Marquette1,2, Paul Hofman1,4,5, 1EA4319, University of Nice Sophia, Nice, France; 2Pneumology, Pasteur Hospital, Nice, France; 4Infectious Diseases, Arèthel Hospital, Nice, France; 6Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; 5Human Biobank, Pasteur Hospital, Nice, France

**Introduction and hypothesis:** Migration of circulating tumor cells (CTC) in the blood stream is certainly an early event occurring during lung carcinogenesis. Chronic obstructive pulmonary disease (COPD), even in early stages, is associated with a higher incidence of lung cancer in smokers and ex-smokers. The purpose of this study was to look for the presence of CTC in a cohort of smokers having a COPD.

**Methods:** The presence of CTC was searched in 50 COPD patients, using both the CellSearch (CS) and the isolation by size of epithelial tumor (ISET) cells methods. Results were compared to the detection of CTC in a group of 30 patients with stage IIB or IV non-small cell lung cancer (NSCLC) and in a group of 30 healthy individuals.

**Results:** 4/50 (8%) COPD patients had CTC (mean=4; range, 2-8) detected by CS and/or ISET methods. 18/30 (60%) of advanced stages NSCLC patients showed CTC (mean=16; range, 2-86). No CTC were detected in healthy individuals.

**Conclusion:** The detection of CTC using the CS and/or the ISET methods is a rare biological event in COPD smoker patients. In this regard, the potentiality of the CS and the ISET methods as tools for detecting early biomarkers of lung carcinogenesis is challenging.

### 4507

**A step towards easier diagnosis of lung cancer: Detection of volatile organic compounds in air releasing tumour samples with ion- and differential mobility spectrometry**

Julia Isabella Kurth1,2, Kaid Darwiche1, Dirk Theegarten1, Jörg-Ingo Baumbach2, Roman Purkhart3, Lutz Freitag1, 1Pneumology, Ruhrlandklinik, University Hospital Essen, Essen, Germany; 2Microfluidics and Clinical Diagnostics, KIST Europe, Sauarbruecken, Germany; 3Clinical Research, Becherconsult, Bernau, Germany

**Introduction:** Lung cancer is the tumour with the highest mortality rate in the western world. Unfortunately, the diagnostic process is still extensive. The detection of Volatile Organic Compounds (VOCs) in air releasing tumour samples might be a method to accelerate the process of gaining first results.

**Objectives:** The goal in this study was to develop a method using VOCs in the detection of characteristic peaks to determine tumour containing tissue and to specify tumour entities with air samples.

**Methods:** Employing an Ion Mobility Spectrometer (IMS) and a Differential Mobility Spectrometer (DMS), 30 tumour and lung samples were placed into an aluminium lung simulator and analysed by the DMS and IMS via side-stream Teflon tube. Tumour containing samples were compared to non-tumour samples from the same individual in order to distinguish between characteristic peaks. Furthermore the peaks were statistically analysed.

**Results:** The results showed various characteristic peaks and clusters in both measuring devices. These were able to differentiate between tumour and non-tumour samples (e.g. peak‘F98‘, p=0,0003 in adenocarcinoma samples), as well as between the tumour entities. In addition certain peaks (e.g.‘F98‘ in the squamous cell carcinoma samples) were lower in the tumour group.

**Conclusion:** VOCs are able to discriminate between tumour entities and also to detect tumour containing tissue. In future research projects IMS and DMS should be compared with a closer view on standardizing peaks in order to and gain further opportunities for more precise tumour detection.